Cost-effectiveness of the personalized cancer drugs dasatinib, imatinib, and nilotinib over time: A systematic review

¹Student Master's Programme Public Health, Department of Medical Informatics, Biostatistics and Epidemiology-IBE, LMU Ludwig Maximilian University of Munich, Munich, Germany,

²Department of Public Health and Health Technology Assessment, UMIT University for Health Sciences, Medical Informatics and Technology, Hall I. T., Austria,

³Area 4 Health Technology Assessment and Bioinformatics, Oncotyrol Center for Personalized Cancer Medicine, Innsbruck, Austria,

⁴Center for Health Decision Science, Department of Health Policy and Management, Harvard School of Public Health, Boston, MA, United States,

⁵Institute for Technology Assessment and Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States